How many papillae in conventional papillary carcinoma?

Bin Xu,Rene Serrette,R Michael Tuttle,Bayan Alzumaili,Ian Ganly,Nora Katabi,Giovanni Tallini,Ronald Ghossein
DOI: https://doi.org/10.1089/thy.2019.0328
IF: 6.506
2019-01-01
Thyroid
Abstract:Background: The percentage of papillae is a crucial criterion in differentiating noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) from papillary thyroid carcinomas (PTCs) and in subclassifying PTC into classic and follicular variant. Since the description of NIFTP, three studies have shown that the presence of any papillae may be associated with nodal metastasis, which led to modification of the NIFTP criterion from Methods: A meticulous histopathologic examination was performed on 235 cases previously diagnosed as unifocal encapsulated PTC (U-EPTC). One hundred of these cases were subjected to BRAF(V600E) and NRAS(Q61R) immunohistochemistry. Results: In our cohort, 27 patients (12%) had lymph node metastasis (N1) at the time of initial resection. Overall, 89% of the tumors in the N1 group contained >= 50% papillae, compared with 13% in the N0/Nx group. Nodal metastases were only present in tumors with >= 1% papillae. In noninvasive U-EPTC (n = 161), N1 disease was seen only in tumors with >= 10% papillae. A higher percentage of papillae within the tumor also correlated with an increased frequency of BRAF(V600E) and decreased rate of NRAS(Q61R). None of the 26 NRAS-positive cases had nodal disease, including the invasive tumors. Among 216 patients with follow-up (median: 5.2 years), 3 patients (1.5%) had distant metastases, all detected at the initial presentation. All three tumors displayed 100% follicular growth, and capsular or vascular invasion. There was no locoregional recurrence in the entire cohort. Conclusion: In U-EPTC, there is a strong correlation between high percentage of papillary growth, presence of nodal metastasis, and BRAF+/RAS- genotype regardless of invasive status. Nodal metastases were not seen in tumors with <1% papillae irrespective of invasive status. These findings indicate that the initial criterion of <1% papillae is still valid for the diagnosis of NIFTP. Reinstituting this criterion will spare a carcinoma diagnosis and unnecessary therapy with its side effects on patients who have negligible clinical risk.
What problem does this paper attempt to address?